SANOFICONR
Sanofi Consumer Healthcare India Limited
Each stock's 10,000-path forecast, rendered as light.
Sanofi Consumer Healthcare India Limited (SANOFICONR) Stock Analysis & Case Study
Is SANOFICONR a good buy? The data-driven verdict.
Sanofi Consumer Healthcare India Limited (SANOFICONR) trades at ₹4,534,on the numbers it worth a closer look, a Downstox Snapshot Score of 58/100.
On the numbers, Sanofi Consumer Healthcare India Limited (SANOFICONR) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 39.4× earnings, ROE of 71.6%, a 56% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SANOFICONR fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SANOFICONR ranks against the 2,373 companies in our screener
- SANOFICONR's market cap of 10,396 Cr ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SANOFICONR's book value of ₹151 ranks in the 64th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SANOFICONR's promoter holding of 71.3% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SANOFICONR's 3-year profit (PAT) growth of 78.0% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SANOFICONR's debt-to-equity ratio of 0.06x is lower than 84% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a 3-year revenue growth figure for SANOFICONR, as of 9 Aug 2026, so it is not ranked here.
Is SANOFICONR overvalued? SANOFICONR P/E vs peers
SANOFICONR trades at 39.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
SANOFICONR share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.9y of SANOFICONR history (-4%/yr drift, 29%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SANOFICONR 2027 | ₹3,246 | ₹4,731 | ₹6,894 | +5% |
| SANOFICONR 2028 | ₹2,930 | ₹4,958 | ₹8,388 | +10% |
| SANOFICONR 2029 | ₹2,682 | ₹5,196 | ₹10,067 | +15% |
| SANOFICONR 2030 | ₹2,555 | ₹5,445 | ₹11,604 | +21% |
| SANOFICONR 2031 | ₹2,418 | ₹5,707 | ₹13,470 | +26% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SANOFICONR goes up, or doubles?
The bull case for SANOFICONR
- SANOFICONR's return on equity of 71.6% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SANOFICONR's return on capital employed of 89.9% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹10,067.
The bear case & risks
- SANOFICONR's P/E of 39.1x is lower than 34% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 30.0× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹2,682.
SANOFICONR volatility & expected range, how bumpy is the ride?
Over the last 1.9 years SANOFICONR compounded at -4%/year with annualized volatility of 29%. That volatility implies a 1-year 80% range of ₹3,246-₹6,894, the honest backbone behind any single price target.
SANOFICONR price forecast, the full 60-month probability fan
SANOFICONR price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SANOFICONR hits common targets within the simulated horizon?
Full multi-horizon detail on the SANOFICONR price target & forecast page.
SANOFICONR Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SANOFICONR scores 5/8, mixed financial health.
SANOFICONR MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy SANOFICONR with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 29.16% | 3.4× |
| Groww | 29.29% | 3.4× |
| DhanCHEAPEST | 29.16% | 3.4× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 100.00% | 1.0× |
| Pocketful | 29.55% | 3.4× |
| Fyers | 30.30% | 3.3× |
| Anand Rathi | 29.16% | 3.4× |
| Bajaj Broking | 31.00% | 3.2× |
| Share India | 29.28% | 3.4× |
Compare every broker on the SANOFICONR MTF page.
About Sanofi Consumer Healthcare India Limited: sector, index & market-cap context
Sanofi Consumer Healthcare India Limited (SANOFICONR) is a small-cap NSE-listed company, with a market capitalisation of ₹10,478 Cr. See more stocks on our screener.
How the SANOFICONR Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Sanofi Consumer Healthcare India Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SANOFICONR analysis, FAQs
Is Sanofi Consumer Healthcare India Limited (SANOFICONR) a good buy?
On the numbers, Sanofi Consumer Healthcare India Limited (SANOFICONR) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 39.4× earnings, ROE of 71.6%, a 56% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SANOFICONR overvalued or undervalued?
SANOFICONR trades at 39.4× earnings, premium versus the ~22× long-run Nifty average.
What is the SANOFICONR share price target for 2031?
SANOFICONR's probability-weighted 2031 median target is ₹5,707, with an 80% range of ₹2,418-₹13,470 (10,000-path Monte-Carlo).
What is the probability SANOFICONR doubles in 5 years?
The modelled probability of SANOFICONR reaching ₹9,028 (2×) within 5 years is 24%.
What is the bull case for SANOFICONR?
SANOFICONR's return on equity of 71.6% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SANOFICONR's return on capital employed of 89.9% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in SANOFICONR?
SANOFICONR's P/E of 39.1x is lower than 34% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 30.0× price-to-book means most of the value is intangible/expectations, not assets on the books.